Education
About Us
Working with TipRanks
Follow Us
biote (BTMD)
NASDAQ:BTMD
BTMD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.76 - $6.98
Previous CloseN/A
Volume19.10K
Average Volume (3M)170.25K
Market Cap
$149.31M
Enterprise Value$267.94M
Total Cash (Recent Filing)$41.70M
Total Debt (Recent Filing)$9.54M
Price to Earnings (P/E)3.6
Beta0.89
Next Earnings
Nov 11, 2025EPS Estimate
0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.10
Shares Outstanding33,280,228
10 Day Avg. Volume243,289
30 Day Avg. Volume170,245
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.79
Enterprise Value/Revenue1.34
Enterprise Value/Gross Profit1.89
Enterprise Value/Ebitda14.74
Forecast
1Y Price Target
$4.57Price Target Upside41.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Market OpportunityThe market opportunity remains attractive and the end consumer remains loyal to BTMD's products even in a choppy macro backdrop.
Product GrowthThe supplements business was a bright spot, growing by 25% due to moving to Amazon.
ValuationAnalyst maintains a Buy rating given the potential for the turnaround and inexpensive valuation.
Bears Say
Procedure RevenueProcedure revenue declined by -8.4% reflecting lower new clinic growth, higher than normal attrition of established clinics, and lower procedure volume.
Revenue GuidanceManagement lowered both revenue and EBITDA outlook and now expects revenue above $190mm vs. $202-$208mm prior and adj. EBITDA above $50mm vs. $59-$64mm prior.
Software TransitionOngoing software transition issues will linger, and it will likely take 2+ quarters for trends to start to show improvement.
biote News
BTMD FAQ
What was biote’s price range in the past 12 months?
biote lowest stock price was $2.76 and its highest was $6.98 in the past 12 months.
What is biote’s market cap?
biote’s market cap is $149.31M.
When is biote’s upcoming earnings report date?
biote’s upcoming earnings report date is Nov 11, 2025 which is in 79 days.
How were biote’s earnings last quarter?
biote released its earnings results on Aug 06, 2025. The company reported $0.1 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.02.
Is biote overvalued?
According to Wall Street analysts biote’s price is currently Undervalued.
Does biote pay dividends?
biote does not currently pay dividends.
What is biote’s EPS estimate?
biote’s EPS estimate is 0.08.
How many shares outstanding does biote have?
biote has 33,280,228 shares outstanding.
What happened to biote’s price movement after its last earnings report?
biote reported an EPS of $0.1 in its last earnings report, beating expectations of $0.08. Following the earnings report the stock price went down -24.352%.
Which hedge fund is a major shareholder of biote?
Currently, no hedge funds are holding shares in BTMD
biote Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.57 (41.93% Upside)
$4.57 (41.93% Upside)
Blogger Sentiment
Bullish
BTMD Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 152.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 8.4%
Last 30 Days ▼ 8.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.00%
12-Months-Change
Fundamentals
Return on Equity
-7.92%
Trailing 12-Months
Asset Growth
12.81%
Trailing 12-Months
Company Description
biote
biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biote-branded dietary supplements; and sterile pellet insertion kits for men and women. The company was founded in 2011 and is headquartered in Irvine, Texas.
BTMD Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with strong performance in dietary supplements and cost management, alongside challenges in procedure revenue and clinic attrition. The strategic reorganization is expected to drive growth, but the impacts are yet to be realized. The flat overall revenue and adjusted guidance indicate ongoing challenges.View all BTMD earnings summariesBTMD Stock 12 Month Forecast
Average Price Target
$4.57
▲(41.93% Upside)
Technical Analysis
Oncology Institute
―
COMPASS Pathways
―
DocGo
―
Airsculpt Technologies
―
Auna S.A. Class A
―
Ownership Overview
43.49% Insiders
9.16% Mutual Funds
27.04% Other Institutional Investors
12.58% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---